WO2025094146 - VASCONSTRICTORS FOR REDUCING OCULAR TOXICITY OF ANTIBODY-MAYTANSINOID CONJUGATES
National phase entry is expected:
Publication Number
WO/2025/094146
Publication Date
08.05.2025
International Application No.
PCT/IB2024/060836
International Filing Date
02.11.2024
Title **
[English]
VASCONSTRICTORS FOR REDUCING OCULAR TOXICITY OF ANTIBODY-MAYTANSINOID CONJUGATES
[French]
VASOCONSTRICTEURS POUR RÉDUIRE LA TOXICITÉ OCULAIRE DE CONJUGUÉS ANTICORPS-MAYTANSINOÏDE
Applicants **
IMMUNOGEN SWITZERLAND GMBH
Inventors
WESTIN, Eric
ZWEIDLER-MCKAY, Patrick
WARBINGTON, Alexandra
Priority Data
63/595,394
02.11.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5519 | |
| EPO | Filing, Examination, Granting | 102878 | |
| Japan | Filing, Examination, Granting | 4860 | |
| South Korea | Filing, Examination, Granting | 7710 | |
| USA | Filing, Examination, Granting | 28190 |
Total:
149,157
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides methods of administering antibody-maytansinoid conjugates (AMCs) comprising administering an effective amount of the AMC in combination with a vasoconstrictor. Ocular toxicities associated with the AMCs can be significantly reduced, without adversely effecting therapeutic efficacy, using such methods.[French]
La présente divulgation concerne des méthodes d'administration de conjugués anticorps-maytansinoïde (AMC) comprenant l'administration d'une quantité efficace des AMC en combinaison avec un vasoconstricteur. Les toxicités oculaires associées aux AMC peuvent être significativement réduites, sans nuire à l'efficacité thérapeutique, à l'aide de tels procédés.